Previous close | 19.16 |
Open | 19.92 |
Bid | 20.05 x N/A |
Ask | 20.20 x N/A |
Day's range | 19.92 - 19.92 |
52-week range | 13.20 - 21.90 |
Volume | |
Avg. volume | 56 |
Market cap | 2.733B |
Beta (5Y monthly) | -0.05 |
PE ratio (TTM) | 1,992.00 |
EPS (TTM) | 0.01 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 16 June 2016 |
1y target est | N/A |
Indivior PLC (INDV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Indivior PLC (LSE/Nasdaq: INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced respiratory depression, which is the major cause of deaths due to opioid overdose. The study, "Reversal of opioid-induced respiratory depression in healthy volunteers: comparison of intranasal nalmefene and intranasal naloxone", was published in the Journal of Clinical Pharmacology (Reversal of Opioid‐Induced Respiratory Depression in Healthy Volunteers:
Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.